Johnson & Johnson is set to lead Delix Therapeutics' $85 million Series C, signaling major pharma backing for non-hallucinogenic neuroplastogens

Johnson & Johnson is set to lead Delix Therapeutics' $85 million Series C, marking a significant pharma move into non-hallucinogenic neuroplastogens. Delix develops compounds designed to promote neuroplasticity without producing the subjective effects associated with classic psychedelics, positioning the company at the intersection of psychiatric drug development and psychedelic-inspired neuroscience. The financing suggests growing institutional confidence in treatments that aim to capture therapeutic mechanisms linked to psychedelic research while avoiding hallucinogenic effects and the operational complexity of monitored dosing sessions. That shift matters for drug developers, regulators, and investors because it could expand the commercial path for next-generation mental health therapies beyond the classic psychedelic model. Delix's approach reflects a broader industry trend toward scalable, patentable compounds that target depression and related disorders through novel mechanisms. Johnson & Johnson's involvement adds strategic weight, given its established position in neuropsychiatry and ketamine-based treatment through Spravato, and signals that large pharmaceutical players are watching this field closely.